Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the research and development of Bryostatin-1 and its analogs for the treatment of neurodegenerative diseases and developmental disorders. Established in 2012, the company focuses on leveraging the therapeutic potential of Bryostatin-1, which acts by activating protein kinase C (PKCϵ) to stimulate synaptic growth factors, enhance amyloid-β degradation, and prevent the transformation of Tau into neurofibrillary tangles. Synaptogenix is currently advancing its pipeline through clinical testing for Alzheimer's disease and evaluating the drug’s efficacy for other conditions, including Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which are in various stages of pre-clinical development.
CannaSoul Analytics
Venture Round in 2023
CannaSoul Analytics is a pioneer in the analysis of cannabis-based products, treatments, and pharmaceuticals, founded by Shmuel Mandel in 2018. The company specializes in the comprehensive analysis of over 100 cannabinoids and 100 terpenes, as well as offering unique endocannabinoid analysis across various matrices. CannaSoul is dedicated to advancing drug discovery through the development of botanical medicine and therapeutics derived from natural compounds. Its services include cannabis molecular analysis, intellectual property licensing, and clinical and pre-clinical trials. Additionally, CannaSoul engages in the screening of cannabis and psilocybin extracts, isolated cannabinoids, and novel molecules using various cell line models, thereby facilitating the integration of botanical medicine into the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.